2021 Annual Meeting | C39 - Multiple Sclerosis Therapy: Disease-modifying Treatment
Program Materials Program Evaluations
08:00 AM - 08:50 AM EDT | Speaker |
MS Therapy: Disease-modifying Treatment
Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD |
08:50 AM - 09:00 AM EDT | Q&A |
Live Q&A
Jacqueline Bernard, MD, FAAN, Michael A. Lane, MD |
Jacqueline Bernard, MD, FAAN | Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Bernard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Bernard has received publishing royalties from a publication relating to health care. |
Michael A. Lane, MD | Dr. Lane has nothing to disclose. |
Nancy J. Newman, MD, FAAN | Dr. Newman has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for GenSight. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chiesi. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke. Dr. Newman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurophth. The institution of Dr. Newman has received research support from GenSight. The institution of Dr. Newman has received research support from Chiesi/Santhera. The institution of Dr. Newman has received research support from NINDS/NIH. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. Dr. Newman has received publishing royalties from a publication relating to health care. |